SWOG clinical trial number
SWOG-9444
Gastrointestinal Tumor Repository Protocol, Ancillary
Closed
Phase
Research committees
Gastrointestinal Cancer
Eligibility Criteria Expand/Collapse
Pts must be enrolled on a Southwest Oncology Group coordinated GI treatment protocol. If pt is found inelig for the specific trx protocol, they will also be inelig for this protocol. Pts must have adequate tissue available for this study, defined as: at least one (1) formalin fixed, paraffin-embedded block from a representative area of the primary tumor; one (1) formalin fixed, paraffin-embedded block from normal gastrointestinal mucosa or from a normal lymph node; one (1) formalin fixed, paraffin-embedded whole lymph node if metastases are present.Pts must be enrolled on a Southwest Oncology Group coordinated GI treatment protocol. If pt is found inelig for the specific trx protocol, they will also be inelig for this protocol. Pts must have adequate tissue available for this study, defined as: at least one (1) formalin fixed, paraffin-embedded block from a representative area of the primary tumor; one (1) formalin fixed, paraffin-embedded block from normal gastrointestinal mucosa or from a normal lymph node; one (1) formalin fixed, paraffin-embedded whole lymph node if metastases are present.
Other Clinical Trials
SWOG Clinical Trial Number
S2303
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
SWOG Clinical Trial Number
CTSU/A022101
A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
Phase
SWOG Clinical Trial Number
S2107
Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
Accrual
100%
Open
Phase